

16. Other items or information:

EL 239201781 US
Express Mail Label Number December 3, 2001

Date of Deposit

Form PTO-1390-MOD (REV 10-96)			Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-30970A									
-		TRANSMITTAL LETTER TO 1	U.S. APPLICATION NO. (# known, see 37 CFR 1.5)										
		DESIGNATED/ELECTED O CONCERNING A FILING UN	10/009008										
		NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED									
		P00/05058	2 June 2000 (02.06.00)	4 June 1999 (04.06.99)									
TITLE OF INVENTION BETA2-ADRENOCEPTOR AGONISTS													
APPLICANT(S) FOR DO/EO/US													
CUENOUD ET AL.													
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.	\boxtimes	This is a FIRST submission of items cond	cerning a filing under 35 U.S.C. 371.										
2. 3.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay											
J .) and PCT Articles 22 and 39(1).												
4.	\boxtimes	A proper Demand for International Prelim	ninary Examination was made by the 19th	h month from the earliest claimed priority									
5.	571	date. A copy of the International Application as filed (35 U.S.C. 371(c)(2))											
•	23	a. [] is transmitted herewith (required only if not transmitted by the International Bureau).											
		b. As been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)).											
6.													
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).											
		a. are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau.											
		c. have not been made; however, the time limit for making such amendments has NOT expired.											
	_	d. X have not been made and will not be made.											
8. 9.	☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). ☐ An unexecuted Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).												
	Ö												
		371(c)(5)).											
Iten	ns 1	1. to 16. below concern document(s) or	information included.										
11.		An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.										
12.		An assignment document for recording.	A separate cover sheet in compliance w	ith 37.CFR 3.28 and 3.31 is included.									
13.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminar	ry amendment.										
14.	×	Bib Data Sheet.											
15.		A change of power of attorney and/or ad-	dress letter.										

M PCT/PTO 0 3 DEC 2001 4-30970A

U.S. APPLICATION NO. WYOM DELICATION NO. 100 PCT/EP00/05058 4-30970A								OCKET NUMBER				
17. X The following fee	CALCULATIONS PTO USE ONLY											
BASIC NATIONAL FEE												
Search Report ha												
International preliminary examination fee paid to USPTO (37 CFR 1.482)												
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740												
Neither internation international sear												
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100												
ENTER APPROPRIATE BASIC FEE AMOUNT =												
Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).												
CLAIMS		RFILED	NUMBER EXTRA		RATE							
Total claims	21	- 20 =	1	<u> </u>	\$	18	\$	18				
Independent claims	2	-3 =	0	X	\$	84 280	\$					
MULTIPLE DEPENDEN	\$	908										
	-	- 700										
Reduction of 1/2 for filing	g by small en	itity, if applica	ble. Verified Small Entity	Statem	ent must a	also be	\$					
filed (Note 37 CFR 1.9,	\$	908										
Processing fee of \$130	-											
the earliest claimed prior	s											
the current diameter pine	\$	908										
Can for encording the or	cheed assign	nment /37 CE	R 1.21(h)). The assignm			FEE =						
by an appropriate cover	sheet (37 Cf	R 3.28, 3.31)	. \$40 per property	• • • • • • • • • • • • • • • • • • • •		+	\$					
by an appropriate core.	0.1000 (0.1		TOTAL F	EES E	NCLOS	ED =	\$	908				
		- <u>-</u>						int to be: refunded	\$			
								charged	\$			
			4	is	ologed							
a. A check in the			to cover the above fe									
fees. A duplication	ate copy of th	ils form is enc										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.												
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently: Thomas Hoxie Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 Send all correspondence to the address associated with Authority in the currently: Carol A. Loeschorn Attorney for Applicants Reg. No. 35,590 (908) 522-6932												